Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain training tailored to you: a new approach for schizophrenia

NCT ID NCT01945333

Disease control Sponsor: New York State Psychiatric Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study tests a personalized cognitive remediation program for people with schizophrenia or schizoaffective disorder. Participants work on computer-based cognitive exercises and take part in group discussions to improve thinking skills like memory and attention. The goal is to see if tailoring the training to each person's needs is practical and helps with daily functioning.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cognitive remediation therapy
What this could lead to
If successful, this could lead to more effective, personalized cognitive training that helps people with schizophrenia improve memory, attention, and daily living skills.
What could go wrong
This is an early pilot study focused on feasibility, so results may not confirm effectiveness. The small size and lack of a control group limit what can be concluded.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

115 people

The number who actually took part.

Start date

Sep 2013

Finished

Mar 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnostic and Statistical Manual-IV (DSM-IV) diagnosis of schizophrenia or schizoaffective disorder 2. Age 18 to 65 3. English speaking 4. Psychiatrically stable, verified by current living/treatment status Exclusion Criteria: 1. Indication of mental retardation, determined by estimated IQ of less than 70 2. Hearing or visual impairment that precludes completing assessments 3. Neurologic illness that may affect brain physiology (e.g. Parkinson's, seizure disorder, epilepsy) 4. Current substance dependence symptoms in the past 6 weeks 5. Participation in cognitive remediation in the 12 months prior to study entry.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Schizoaffective disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Psychotic Disorders schizoaffective disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Schizoaffective disorder Schizophrenia

Contacts and locations

Locations

  • FEGS Bronx Mental Health Clinic

    The Bronx, New York, 10467, United States

  • Institute for Community Living

    Brooklyn, New York, 11207, United States

  • Nyspi/ Cumc

    New York, New York, 10032, United States

  • The Bridge Inc

    New York, New York, 10040, United States

  • Williamsburg Clinic

    Brooklyn, New York, 11206, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.